| Shire PLC | 62,000 | The new entity would be a global pharmaceutical giant with its roots in Japan, as Weber envisions it along with becoming a leader in gastroenterology, neuroscience, oncology, rare diseases and blood-derived therapies, used for serious conditions such as hemophilia. | Takeda Pharmaceutical Company Limited | Acquisition | Ireland |
| Sivantos Pte. | 8,200 | Combined businesses to become a global R&D powerhouse as well as an innovation leader with approximately 800 specialists and abundant resources to further accelerate innovation of hearing instruments and tailored solutions including by leveraging its leading digital platform | Widex A/S | Merger Agreement | Denmark |
| Meridian Health | 2,500 | Meridian is one of the largest privately held, for-profit managed care organizations in the U.S. and serves approximately 1.1 million Medicaid, Medicare Advantage (MA), integrated dual-eligible and Health Insurance Marketplace members as of May 1, 2018 in Michigan, Illinois, Indiana and Ohio. | WellCare Health Plans, Inc. | Acquisition | United States |
| MedReleaf Corp. | 2,470 | The proposed Transaction brings together two of Canada's premier cannabis companies with fully-aligned strategic visions and production philosophies, as well as complementary assets, distribution networks, products, and capabilities. | Aurora Cannabis Inc | Acquisition | Canada |
| ARMO BioSciences | 1,600 | The acquisition will bolster Lilly's immuno-oncology program through the addition of ARMO's lead product candidate, pegilodecakin, a PEGylated IL-10 which has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. | Eli Lilly and Company | Acquisition | United States |
| BeneVir Biopharm | 1,040 | BeneVir engineers oncolytic viruses through the T-Stealth™ platform to overcome the barrier of the body’s immune system. Janssen intends to advance pre-clinical candidates as standalone therapies and in combination with other immunotherapies for the treatment of solid tumor cancers | Janssen Biotech, Inc. | Acquisition | United States |
| Bicycle Therapeutics | 1,000 | The original collaboration was signed in late 2016 and with the expansion has a potential value in excess of $1 billion. Under the terms of the collaboration Bicycle is responsible for identifying Bicycles® for an undisclosed number of respiratory, cardiovascular and metabolic disease targets specified by AstraZeneca, while AstraZeneca is responsible for further development and product commercialization. The expansion provides additional disease targets and triggers an undisclosed milestone paym | AstraZeneca plc | Partnership Expansion | United Kingdom |
| Lodo Therapeutics Corp. | 969 | Compounds derived from natural products comprise a significant proportion of the small molecule drugs used to treat cancer, infections and chronic illnesses such as Type 2 diabetes. Rather than relying on culturing known strains of bacteria, Lodo Therapeutics’ genome-based approach leverages the power of microbial evolution to identify novel, naturally occurring compounds that have therapeutic potential in the treatment of cancer and drug-resistant bacterial infections. This approach is expected | Genentech (Roche Group) | Collaboration | United States |
| Ligand Pharmaceuticals Inc. | 650 | Ligand expects to use the remainder of the net proceeds from the offering of the notes to acquire or invest in complementary businesses, companies, products and technologies and for working capital and other general corporate purposes, including, without limitation, research and development activities to maintain Ligand’s platform technologies and for development of Ligand’s product candidates being developed internally. | Undisclosed Private Investors | Private Placement | United States |
| Darling Ingredients Inc. | 616 | DG Finance will use the net proceeds from the offering of the Notes, together with borrowings under Darling's revolving credit facility, to repurchase the 2022 Notes validly tendered and accepted for purchase pursuant to the Tender Offer, including the payment of any Accrued Interest and costs and expenses incurred in connection therewith. | Darling Global Finance B.V. | Private Placement | United States |
| AurKa Pharma, Inc. | 575 | Under the terms of the agreement, Lilly will acquire all shares of AurKa Pharma. In return, AurKa Pharma shareholders will receive an upfront payment of $110 million. AurKa Pharma shareholders are also eligible to receive up to $465 million in regulatory and sales milestones should AK-01 gain approval in the U.S. and other markets, and achieve certain sales levels. | Eli Lilly and Company | Acquisition | Canada |
| AstraZeneca PLC | 538 | Luye Pharma will pay $538m in consideration including $260m immediately following closure of the transaction. In addition, a milestone is payable on the successful transition of certain activities to Luye. AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR to Luye Pharma during a transition period. The upfront and future payments will be reported as Other Operating Income in the Company’s financial statements. | Luye Pharma Group | License Agreement | United Kingdom |
| Cara Therapeutics, Inc. | 520 | Cara Therapeutics, Inc. today announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd, a joint company of Vifor Pharma Group and Fresenius Medical Care (NYSE:FMS) that specializes in treatments for CKD. | Vifor Fresenius Medical Care Renal Pharma (VFMCRP) | License Agreement | United States |
| Zymeworks Inc. | 485 | Under the terms of the second agreement, Daiichi Sankyo will acquire licenses to Zymeworks’ Azymetric™ and EFECT™ technology platforms to develop two additional bispecific antibody therapeutics. In exchange, Zymeworks will receive an upfront technology access fee of US$18 million and may receive up to US$466.7 million in potential clinical, regulatory and commercial milestone payments. In addition, Zymeworks will receive up to double-digit tiered royalties on global product sales. | Daiichi Sankyo Company, Limited | License Agreement | Canada |
| F-star Biotechnology Ltd. | 471 | In the ongoing collaboration between F-star and Denali announced in August 2016, the partners are developing Fcabs™ (Fc-domains with antigen-binding) against up to three different transporters in the blood-brain barrier (BBB). | Denali Therapeutics | Option Agreement | Austria |
| InRetail Pharma | 400 | The Company is a leading pharmaceutical platform in the Andean region, with the largest retail pharmacy operation in Peru and one of the largest distribution networks in the Andean region. It operates throughout the pharmaceutical value chain, focusing on retail pharmacies and pharmaceutical distribution and marketing businesses. It also manufactures certain pharmaceutical products. | Citigroup Global Markets | Public Offering | Peru |
| Industrial Development Authority's (IDA) | 381 | An Taoiseach Leo Varadkar, Prime Minister of Ireland today announced that WuXi Biologics, a Hong Kong-listed (2269.HK) global open-access biologics technology platform company, is to invest €325 million and create 400 new jobs over five years in a new biologics drug substance manufacturing facility on the Industrial Development Authority's (IDA) greenfield site in Mullagharlin, Dundalk, Co. Louth. | WuXi Biologics | Manufacturing Investment | Ireland |
| DURECT Corp. | 323 | DURECT received an upfront payment from Sandoz of $20 million at the time the agreement between the two companies became effective in June 2017 and was initially eligible for up to an additional $43 million in payments based on successful development and regulatory milestones (of which $30 million is feasible following the results of the PERSIST Phase 3 clinical trial), and up to an additional $230 million in sales-based milestones. | Sandoz AG (Novartis) | License Agreement | United States |
| Procella Therapeutics, Smartwise (SWIB Holding) | 320 | The aim of the collaboration with the global biopharmaceutical company AstraZeneca is to develop new ways of regenerating parts of the heart muscle that have been damaged by a heart attack, using Procella Therapeutics' stem cell technology, as well as novel catheter injection methods, using Smartwise's Extroducer catheter. | AstraZeneca PLC | Collaboration | Sweden |
| GRAIL, Inc. | 300 | The Series C funding will add to the company’s balance sheet and support ongoing development and validation of products for the early detection of cancer in GRAIL’s clinical research program. | Ally Bridge Group | Series C Financing | United States |
| Advanced Regenerative Manufacturing Institute | 300 | ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue Biofabrication technology to better position the US relative to global competition. ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing | Organovo Holdings, Inc., Samsara Sciences | Partnership | United States |
| Guangdong Techpool Bio-Pharma Co. (Takeda) | 280 | The shareholding is to be acquired in an all-cash, combined Stock Purchase Agreement by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. and a fund managed by SFund International Investment Fund Management Limited, a wholly-owned subsidiary of Guangzhou Industrial Investment Fund Management Co., Ltd. | Shanghai Pharmaceutical, Sunrise Bright Investment Ltd. | Stock Purchase Agreement | China |
| CStone Pharmaceuticals, Inc. | 260 | CStone has built a portfolio of more than ten assets, including four in various clinical stages. In particular, CS1001, China’s first full-length and fully human anti-PD-L1 monoclonal antibody, is completing Phase I dose escalation study and will soon enter registrational trials. | GIC Private Limited | Series B Financing | China |
| Brii Biosciences, Inc. | 260 | Exclusive agreement with Vir Biotechnology, Inc. grants greater China rights for up to four infectious disease assets, Partnership with Alibaba Group's AliHealth to better identify and educate patients, and better connect them to clinics, healthcare resources, and medicines. | ARCH Venture Partners | Launch & Partnerships | China |
| Medigene AG | 259 | Under the revised terms of the agreement, the number of target antigen/MHC restriction combinations for the discovery of specific TCR lead candidates by Medigene will be increased from four to six. As part of this contractual expansion, Medigene will receive an additional one-time payment of USD 8 million. | bluebird bio | Alliance Expansion | Germany |
| Epigen Biosciences, Inc. | 200 | EPGN696 is an orally available, selective LPA1 receptor antagonist under development in diabetic and chronic kidney disease and other chronic diseases associated with metabolic syndrome. | Novo Nordisk A/S | License Agreement | United States |
| Karyopharm Therapeutics Inc. | 162 | The agreement includes the development and commercialization of selinexor and eltanexor for the diagnosis, treatment and/or prevention of all human oncology indications in China and Macau. The agreement also includes the development and commercialization of KPT-9274 in all human oncology indications and verdinexor in human non-oncology indications in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries. | Antengene Corporation | License Agreement | United States |
| Aquinox Pharmaceuticals, Inc. | 155 | Astellas to Obtain Development and Commercialization Rights to Rosiptor, Aquinox’s Lead Drug Candidate, in Japan and Certain Other Countries in the Asia-Pacific Region | Astellas Pharma Inc. | License Agreement | Canada |
| Kiniksa Pharmaceuticals, Ltd. | 152.6 | Kiniksa, a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic medicines for debilitating diseases, has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. | | Public Offering | Bermuda |
| Janssen Pharmaceuticals | 135 | PANCREAZE is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes, including porcine-derived lipases, proteases and amylases. The pancreatic enzymes in PANCREAZE act like digestive enzymes physiologically secreted by the pancreas. PANCREAZE is specifically indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Upon closing, VIVUS will acquire PANCREAZ | VIVUS, Inc. | Asset Acquisition | United States |
| Moderna Therapeutics, Inc. | 125 | Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna | Merck & Co. (MSD) | Expansion of Previous Development and Commercialization Agreement | United States |
| La Jolla Pharmaceuticals, Inc. | 125 | La Jolla will receive $125 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. The agreement was entered into by La Jolla’s wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the agreement against La Jolla or any assets other than GIAPREZA. “This transaction provides us with a strong financial position to support the commercial launch of GIAPREZA, while at the same time furthering the development of LJPC-401 and our other programs,” said | HealthCare Royalty Partners | Royalty Financing | United States |
| Gemini Laboratories, LLC | 117 | Amneal Acquires Gemini Laboratories, LLC and Enters Into Biosimilar Partnership with mAbxience S.L. | Amneal Pharmaceuticals LLC | Acquisition | United States |
| Myonexus Therapeutics, Inc. | 105 | The most advanced of Myonexus’ programs, MYO-101, aims to treat LGMD2E, also known as beta-sarcoglycanopathy, a severe and debilitating form of LGMD characterized by progressive muscle fiber loss, inflammation and muscle fiber replacement with fat and fibrotic tissue. MYO-101 is designed to transfect a gene that codes for and restores beta-sarcoglycan protein with the goal of restoring the dystroglycan complex. | Sarepta Therapeutics | Partnership | United States |
| Portola Pharmaceuticals, Inc. | 100 | Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company has received a $100 million milestone payment from HealthCare Royalty Partners (HCR) following the U.S. Food and Drug Administration (FDA) approval of Andexxa [coagulation Factor Xa (recombinant), inactivated-zhzo] on May 3, 2018. | HealthCare Royalty Partners | Milestone Payment | United States |
| Best Choice Inc. | 90 | Nutriband Inc. is pleased to announce that it has signed an exclusive 20-year, $90 million distribution agreement for its transdermal consumer product lines with Best Choice Inc., a Korean consumer products distributor with a 20-year history of working with major chain retailers, including Costco and Lotte Department Stores. | Nutriband Inc., | Distribution Agreement | Korea |
| Beam Therapeutics, Inc. | 87 | Beam aims to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. | F-Prime Capital Partners | Series A Financing | United States |
| UNITY Biotechnology, Inc. | 85 | Aggregate gross proceeds to the Company were approximately $85.0 million, before underwriting discounts, commissions and estimated offering expenses. All of the shares in the offering were offered by UNITY. UNITY’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “UBX.” | Goldman Sachs & Co. LLC | Public Offering | United States |
| Ansun BioPharma, Inc., | 85 | Ansun plans to use the proceeds from the Series A to fund a Phase 3 clinical trial of its experimental anti-viral medication, DAS181. The FDA has granted both Fast Track status and Breakthrough therapy designation to DAS181, and Ansun is currently in the planning stage of a Phase 3 trial to treat hospitalized, immunocompromised subjects infected with parainfluenza virus. | Sinopharm Healthcare Fund | Series A Financing | United States |
| Evelo Biosciences, Inc. | 85 | Evelo has granted the underwriters a 30-day option to purchase up to an additional 796,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. | | Public Offering | United States |
| Iterum Therapeutics PLC | 80 | Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, today announced the pricing of its initial public offering of 6,150,000 ordinary shares at a price to the public of $13.00 per share, for total gross proceeds of approximately $80 million. | Leerink Partners | Public Offering | Ireland |
| Cortexyme, Inc | 76 | Cortexyme announced the successful completion of a placebo-controlled single ascending dose trial and a multiple ascending dose trial in healthy older volunteers of COR388, the company’s lead small molecule. COR388 is a first-in-class, orally administered bacterial protease inhibitor that targets a specific pathogen discovered in the brains of patients with Alzheimer’s | Sequoia Capital, Takeda Ventures | Series B Financing | United States |
| MEI Pharma, Inc. | 75 | Proceeds from the financing will be used to fund continued clinical development of MEI-401, a selective oral inhibitor of phosphatidylinositol 3-kinase ("PI3K") delta that is expected to enter a single-agent registration study in 2018 for the treatment of adults with relapsed or refractory follicular lymphoma, and for general corporate purposes. | Vivo Capital | Private Placement | United States |
| Scholar Rock Holding | 75 | Scholar Rock Holding, a biotech targeting growth factor inhibition for spinal muscular atrophy, raised $75 million by offering 5.36 million shares at $14, within the range of $13 to $15. At that price, it commands a fully-diluted market value of $350 million. | Cowen & Company | Public Offering | United States |
| FogPharma | 66 | Proceeds from the Series B raise will enable the company to advance its first-in-class beta-catenin inhibitor (iCat) program into Phase 2 development for cancer indications involving Wnt pathway activation. The financing will also be used to advance clinical development of its first-in-class Cbl-b inhibitor program and a third as-yet-undisclosed program through IND-enabling studies, and FogPharma's drug discovery platform for three additional, distinct and differentiated forms of cell-penetrati | 6 Dimensions Capital | Series B Financing | United States |
| Celsius Therapeutics, Inc. | 65 | Celsius’ fundamentally new approach aims to combine the power of single-cell genomic sequencing with computational algorithms to discover first-in-class precision therapies for which the company applies a systematic approach, starting with single-cell sequencing on defined patient samples to identify and understand the individual cells and their interactions that cause disease. | Third Rock Ventures | Series A Financing | United States |
| Sublimity Therapeutics Ltd. | 64 | The proceeds from the financing will support the clinical development of STI-0529. Sublimity intends to initiate a global Phase 2b dose-ranging study designed to evaluate the safety and efficacy of STI-0529 in patients with moderate to severe ulcerative colitis. | OrbiMed | Funding | Ireland |
| Casma Therapeutics, Inc. | 58.5 | Casma is pioneering novel strategies to boost autophagy to arrest or reverse the progression of rare genetic diseases and broader pathologies, including neurodegeneration | Third Rock Ventures | Series A Financing | United States |
| Akili Interactive | 55 | The financing follows the positive top-line results in December 2017 from Akili’s multicenter, randomized, controlled pivotal study of AKL-T01, the Company’s flagship investigational product designed to treat pediatric attention deficit/hyperactivity disorder (ADHD). Akili is planning to file AKL-T01 for clearance by the U.S. Food and Drug Administration (FDA) in the coming months, which would enable it to be prescribed by physicians as a stand-alone treatment for children and adolescents with A | Temasek | Funding | United States |
| Neurimmune | 50 | Biogen will make a one-time $50 million payment to Neurimmune in exchange for a 5% reduction in the original royalty rates on potential commercial sales of aducanumab, which follows the 15% reduction in royalty rates announced in October 2017. | Biogen | Option Exercise Agreement | Switzerland |
| BioClin Therapeutics, Inc | 50 | The proceeds from this financing will be used to advance the company’s lead development candidate, B-701, for the treatment of patients with metastatic bladderncancer, or metastatic urothelial carcinoma (mUC). | Sofinnova Ventures | Series B Financing | United States |
| Cidara Therapeutics, Inc. | 50 | The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly known as CD101 IV, through late stage clinical trials, and developing its antibody-drug conjugates for the treatment of multi-drug resistant Gram-negative bacterial infections. Cidara is developing its antibody-drug conjugates as part of its novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a | Biotechnology Value Fund, L.P. | Public Offering | United States |
| Ardelyx, Inc. | 50 | Ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. Ardelyx's renal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of hyperkalemia. | Solar Capital Ltd. | Loan Agreement | United States |
| Nohla Therapeutics | 45 | Nohla intends to use the proceeds to complete the ongoing Phase 2 trials of its lead candidate, dilanubicel (NLA101), in allogeneic transplant and chemotherapy-induced myelosuppression, as well as support Phase 3 trial and commercial manufacturing needs. Proceeds will also be used to advance the company’s novel cell-based therapy platform and pipeline. | Celgene Corporation | Series B Financing | United States |
| ASLAN Pharmaceuticals Limited | 42.2 | ASLAN expects to use the net proceeds from the offering to continue to invest in the clinical development of its product candidates, including for the following planned and ongoing clinical trials: global pivotal clinical trial for varlitinib in biliary tract cancer; China pivotal clinical trial for varlitinib in biliary tract cancer; global phase 2/3 clinical trial for varlitinib in gastric cancer; global clinical trials for ASLAN003 in AML; and ASLAN004 preclinical and phase 1 clinical trials. | Leerink Partners | Public Offering | Singapore |
| Escient Pharmaceuticals | 40 | Strategic focus on unleashing therapeutic potential of specific orphan GPCRs, including novel family of Mas-Related G-Protein Receptors (Mrgprs) | The Column Group | Series A Financing | United States |
| Accent Therapeutics | 40 | The company is using small molecule drugs that inhibit the enzymes that perform modifications on RNA. Accent Therapeutics was established to create innovative therapeutics in the rapidly advancing area of epitranscriptomics – the role of RNA structure, stability, function and translation in cell biology. Recent studies have linked certain human cancers to the activity of particular RMPs, providing a rich new target space for drug development. | The Column Group | Series A Financing | United States |
| HitGen | 39 | HitGen is a platform company based on its leading DNA-encoded library (DELs) technology for innovative drug discovery research. Its continuously expanding DELs consist of over 900 individual libraries with over 200 Bn novel small molecules, and is among the largest and most diverse screening libraries in the world. | CDH Investments | Series B Financing | China |
| HiFiBiO Therapeutics | 37.5 | HiFiBiO Therapeutics works on generating breakthrough immune modulators to address unmet medical needs around the world. The company continues to establish multiple strategic partnerships with leading pharmaceutical and biotechnology companies to drive an innovative pipeline of antibody drugs that leverage its proprietary single-B-cell functional antibody discovery CelliGOTM platform. | Sequoia China | Series B Financing | United States |
| Eiger Biopharmaceuticals Inc. | 37.2 | Eiger plans to use the net proceeds from the offering to fund its planned Phase 3 clinical trial of lonafarnib in Hepatitis Delta Virus infection, regulatory development of lonafarnib related to the treatment of Hutchison-Gilford Progeria Syndrome, and for working capital and other general corporate purposes. | Piper Jaffray & Co. | Public Offering | United States |
| Medigene AG | 37 | Medigene intends to use the net proceeds of this placement to expand the Company's ongoing clinical program with its T-cell receptor modified T cells (TCR-T) and to progress its pipeline of potential TCR-T candidates for future clinical development. | QVT Financial LP | Private Placement | Germany |
| CAMP4 Therapeutics | 30 | CAMP4 is focusing its efforts to scale its proprietary 4-D Gene Circuity Platform across all human cell types relevant to disease. “The machinery that controls activation of the 24,000 genes in the human body can be codified by CAMP4’s platform into a discrete set of combinatorial rules using signaling pathways." | Andreessen Horowitz | Series A Financing | United States |
| Xenikos B.V. | 30 | Xenikos B.V. is a clinical-stage biopharmaceutical company which is currently focused on developing a novel therapy for treating acute graft-versus-host disease (aGVHD). Xenikos's lead product candidate, T-Guard, will be undergoing clinical Phase 3 registration trials in the US and EU, post this funding round. | Medicxi Ventures | Series B Financing | The Netherlands |
| The Ensign Group, Inc. | 29 | The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and assisted living services, physical, occupational and speech therapies, home health and hospice services and other rehabilitative and healthcare services at 234 healthcare facilities, 22 hospice agencies, 20 home health agencies and four home care businesses in California, Arizona, Texas, Washington, Utah, Idaho, Colorado, Nevada, Iowa, Nebraska, Oregon, Wisconsin, Kansas, South Carolina, a | National Health Investors, Inc. | Purchase Agreement | United States |
| NeuroproteXeon | 28 | The agreement includes a multi-tiered royalty and 23 million euros in milestone payments. The two key milestone payments are on approval for PCAS from the European Medicines Agency ("EMA") and when Linde reaches cumulative sales of 100 million euros – provided this occurs in the first four years following approval. | Linde AG | Distribution Agreement | United Kingdom |
| CellCentric | 26 | CellCentric has raised $26 million in private financing to fund clinical testing of its first-in-class oncology drug candidate CCS1477. The funds will be used to test the novel p300/CBP inhibitor in late stage, treatment-resistant prostate cancer (up to Phase IIb). | Morningside Venture Investments | Private Placement | United Kingdom |
| Refuge Biotech | 25 | The funds from the Series B will support advancement of cell therapies developed with Refuge's receptor-dCas platform, which utilizes a mutated or dead Cas9 (dCas) as a targeting mechanism to enable precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). | 3SBio | Series B Financing | United States |
| Avedro, Inc. | 25 | “This new funding brings together an exceptional syndicate of investors who are committed to helping us achieve this goal. It will allow us to accelerate adoption of the only FDA-approved cross-linking treatment and the development of our next-generation corneal remodeling applications.” | Lilly Asia Ventures | Funding | United States |
| Undisclosed Researchers | 24 | These are the largest awards specifically designed for brain tumour research in the UK, which encourage multidisciplinary approaches from scientists. The aim is to accelerate research in a bold and innovative way that would not be possible through traditional funding schemes. | Cancer Research UK, The Brain Tumour Charity | Grants & Awards | United Kingdom |
| EIP Pharma | 20.5 | Proceeds from the financing will be used to further advance development of neflamapimod, an oral small molecule inhibitor of the intra-cellular enzyme p38 MAP kinase alpha (p38 alpha) being studied in Alzheimer's disease. In times of stress and disease p38 alpha is expressed in neurons, and irregular p38 alpha activity within the neuron can contribute to synaptic dysfunction. | Access Industries | Series B Financing | United States |
| Propeller Health | 20 | Proceeds from the financing will support Propeller’s investment in its pipeline of digital therapeutics and additional connected devices for the treatment of chronic respiratory disease, an area of continued market growth for the company. Propeller will also begin to develop digital medicines for new therapeutic areas. | Aptar Pharma | Funding | United States |
| Surface Pharmaceuticals | 20 | Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments, by seeking FDA approval for three drug candidates. | Flying L Partners | Series A Financing | United States |
| Lion TCR | 20 | The proceeds from this fundraising will be primarily used to advance its on-going clinical trials of its lead candidate LioCyx™ (personalized HBV specific TCR T cell therapy against HCC) in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumours and clearance of chronic hepatitis B. | Yashang Capital, Westlake Ventures Capital | Series A Financing | Singapore |
| Lava Therapeutics | 19 | The funding will support development of LAVA’s proprietary pipeline of bispecific gamma-delta (??) T cell engagers for the treatment of cancer. ?? T cells are a potent class of proinflammatory immune effector cells and one of two main categories of T lymphocytes effective to treat both solid and hematological malignancies. | Gilde Healthcare | Institutional Financing | The Netherlands |
| Karyopharm Therapeutics | 19 | Karyopharm intends to use the net proceeds of the offering: to support continued clinical development of selinexor in hematologic malignancies and solid tumors as a single agent and in combination with approved and experimental therapies; to conduct activities to support regulatory submissions for oral selinexor as a new treatment for patients with penta-refractory multiple myeloma | Canaccord Genuity | Public Offering | United States |
| Rain Therapeutics | 18.4 | Rain plans to use the proceeds to advance the clinical development of its lead program, Tarloxotinib (Tarlox), in patients with EGFR and ErbB Exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The company intends to commence a Phase 2 study in patients with EGFR and ErbB Exon 20 insertion mutations in NSCLC in the first half of 2019. | Biotechnology Value Fund (BVF) | Series A Financing | United States |
| Kronos Bio, Inc. | 18 | Kronos is researching and developing first-in-class therapies against historically intractable targets through high-throughput screening strategies for chemical modulators of transcription factors and other recalcitrant targets in oncology. Kronos is currently advancing two preclinical programs built upon hits identified from the SMM platform, targeting MYC and the Androgen Receptor (AR). | Kite Pharma | Seed Financing | United States |
| Oncobiologics, Inc. | 15 | Oncobiologics intends to use the net proceeds from the private placement primarily for the initiation of clinical trials for ONS-5010, an innovative monoclonal antibody (mAb) product candidate under development, the expansion of the BioSymphony™ Platform for providing contract development and manufacturing services (CDMO), and for working capital and general corporate purposes. | GMS Tenshi Holdings Pte. | Private Placement | United States |
| NOXXON Pharma | 13 | These funds will be used for the clinical development of NOX-A12 in advanced solid tumors, as the company proceeds to conduct the NOX-A12 clinical trial in collaboration with Merck & Co. Inc./MSD in patients with metastatic colorectal and pancreatic cancer who generally do not respond to checkpoint inhibitors alone. | Kreos Capital | Private Placement | Germany |
| SeneFill Facility | 12 | Novasep, a leading supplier of services and technologies for the life sciences industry, announces a €10M investment in a commercial fill & finish facility for viral vectors, mAbs and other low-volume biologics. The facility will be located in Seneffe (Belgium) and will be operational in H2 2019. This project is part of Novasep’s Rise-2 strategic growth cycle. It complements a €27M investment in a new commercial scale viral vector production facility in Seneffe (Belgium) that will be fully quali | Novasep Inc. | Manufacturing Investment | France |
| AbSci | 12 | The financing will enable AbSci to expand its R&D and to scale up capacity in order to meet the growing demand from its large pharma and biosimilar partners. AbSci's breakthrough protein expression platform, SoluPro™, has demonstrated the ability to accelerate biopharmaceutical discovery and development timelines as well as dramatically reduce biopharmaceutical manufacturing costs. | Phoenix Venture Partners | Series C Financing | Canada |
| Acousia Therapeutics | 11.8 | The company’s most advanced drug candidate ACOU085 is being developed for clinical application in otoprotection (cisplatin-related) and will be profiled in functional improvement of hair cells. | LBBW Venture Capital | Series B Financing | Germany |
| OncoNano Medicine, Inc. | 11.7 | OncoNano is using pH variability, a simple and robust biomarker, to detect and treat diseased tissue. By targeting pH, a clear delineation between diseased and healthy tissue can be digitalized to develop a broad range of targeted applications. | Salem Partners | Series A Financing | United States |
| Icagen, Inc. | 11 | The CF Foundation brings extensive resources and expertise to the project and, additionally, has awarded Icagen up to USD $11 million to support an integrated, multi-year drug discovery initiative. Icagen expects to screen over 2 million compounds as well as leverage its state-of-the-art in silico drug discovery platform to interrogate an additional ten million virtual structures for molecules that suppress nonsense mutations. | Cystic Fibrosis Foundation | Grants & Awards | United States |
| Vesper Medical, Inc. | 10.5 | Vesper Medical plans to use the proceeds from this financing to complete the development of its Vesper Duo Venous Stent System™ inclusive of the in vivo testing necessary to obtain the approvals required for clinical testing of the Vesper Duo™ stents. | New Enterprise Associates | Series A Financing | United States |
| Mesoblast Limited, Cartherics Pty Ltd | 9.6 | Mesoblast will make an in-kind contribution of its allogeneic cell platform technology as well as providing scientific expertise. Mesoblast is a global leader in allogeneic cellular medicines with three Phase 3 trials in advanced heart failure, chronic lower back pain and acute graft versus host disease. | Australian Government’s Cooperative Research Centres Program (CRC-P) | Collaboration | Australia |
| Starpharma | 9.2 | Mundipharma will register and launch VivaGel® BV as part of the popular BETADINE® range, which is sold in more than 120 countries. BETADINE® has a market leading position in Feminine Care and this licence enables Mundipharma to develop the consumer market for VivaGel® BV in rapidly developing markets across Asia, the Middle East, Africa and Latin America, where demand for trusted intimate health and hygiene products is growing. | Mundipharma GmbH | License Agreement | Australia |
| Indiana University's Richard M. Fairbanks School of Public Health | 7 | Lilly and Indiana University’s Fairbanks School of Public Health at IUPUI are implementing the pilot with Eskenazi Health, Local Initiatives Support Corporation Indianapolis (LISC) and the Marion County Public Health Department. Borrowing from Lilly’s global health efforts, the pilot will deploy a model that uses newly hired community health care workers to help identify people with diabetes and connect them with quality care. | Eli Lilly and Company | Diabetes Prevention and Management Collaboration | United States |
| OnKure, Inc. | 7 | OnKure's platform transforms naturally occurring, biologically active lead compounds into commercial drugs that address a variety of diseases with an emphasis on oncology. At the heart of OnKure's solution to Class 1 histone deacetylase inhibition is a molecule (OKI-179) that parallels the potency and selectivity of Romidepsin (Istodax), the most potent Class 1 biased histone deacetylase inhibitor currently approved by the FDA. | Delian Capital | Series A Financing | United States |
| CytRx Corporation | 7 | CytRx is rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used anti-cancer drug | H.C. Wainwright & Co. | Registered Direct Offering | United States |
| NeuCyte Inc. | 6.7 | NeuCyte intends to use the proceeds of the Series A financing to further develop their SynFire® in vitro CNS drug discovery platform for the identification of novel drug targets for Fragile X Syndrome (FXS) and other genetically defined neurological disorders. NeuCyte is also seeking strategic partnerships to rapidly advance their programs to a clinical stage. | Cowin Venture | Series A Financing | United States |
| Harvard University | 6.5 | The LabXchange platform, which will launch with a focus in biology, will offer digital instruction and virtual lab experiences to high school and college students, enabling them to gain meaningful exposure to the scientific process. It will also include online networking focused on collaboration and mentoring. | Amgen Foundation | Grants & Awards | United States |
| Melinta Therapeutics | 6.2 | Melinta’s novel pyrrolocytosine compounds are a novel class of antibiotics from the company’s ESKAPE pathogen Program, a program based on Melinta’s proprietary drug discovery platform focused on developing breakthrough antibiotics for bacterial “superbugs” by targeting the bacterial ribosome. | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) | Partnership | United States |
| Casetabs | 6 | Launched in 2016, Casetabs’ award-winning surgery coordination application is changing how surgeries are coordinated by ensuring everyone involved in a case is continuously and instantly on the same page. In just two years, Casetabs has grown exponentially from five centers to 100 centers and 500 physician practices, almost entirely through referrals. | Nueterra Capital | Series A Financing | United States |
| Karo Pharma | 6 | In December 2011, Karo Pharma entered a research collaboration and licensing agreement with the American company Pfizer. The aim of this agreement is to discover and develop compounds that inhibit the activity of the nuclear hormone receptor RORgamma, for treatment of autoimmune diseases. The development is lead by Pfizer according to the terms of the agreement. Pfizer has global exclusive rights to use, dev | Pfizer | Milestone Payment | Sweden |
| Genoox | 6 | In the past year, Genoox has rapidly grown its customer base and initiated partnerships with medical centers and research facilities, including the Center for Genetic Medicine Research at Children's National Medical Center and the University of Michigan | Triventures | Funding | United States |
| Cidara Therapeutics, Inc. | 5.5 | The grant will fund the continued research and development of Cidara’s innovative Cloudbreak™ antibody-drug conjugate (ADC) platform to identify novel immunotherapy agents for the treatment and prevention of serious and life-threatening multi-drug resistant (MDR) Gram-negative bacterial infections in high-risk patient populations. | National Institute of Allergy and Infectious Diseases (NIAID) | Grants & Awards | United States |
| Marker Therapeutics | 5.1 | The proposed transaction will be a merger-of-equals under which the stockholders of TapImmune and Marker will each own approximately 50% of the combined company, prior to any issuances of additional shares in a contemplated financing. | TapImmune | Merger Agreement | United States |
| West Virginia University (WVU) | 5 | Collaboration aims to demystify STEM and broaden its perceived application. Program will leverage 4-H infrastructure and WVU STEM outreach, reaching every county in West Virginia. Mylan commits a $5 million charitable contribution over 10 years to empower West Virginia children to be Curious, Active, Resilient and Engaged (CARE). | Mylan N.V. | Collaboration | United States |
| Mobidiag Ltd. | 4.7 | By combining in-house expertise and unique patented technologies, Mobidiag has now the means to develop a revolutionary assay to detect sepsis causing microbes and antibiotic resistances directly from blood. | Business Finland | Funding | Finland |
| Novacyt | 4.7 | Novacyt, a global specialist in clinical diagnostics, announces that it has obtained on 29 May 2018 a new unsecured loan facility of 4.0 million euros from a French institutional investor | | Unsecured Debt Facility | France |
| SiSaf | 4.3 | The Company specializes in drug delivery technologies, and SiSaf’s ProSilic® bio-courier technology is a novel method of drug delivery that is based on a patented hybrid of porous silicon and liposomes. ProSilic® can take the most challenging molecules to their target and optimises their efficacy and safety | Vickers Venture Partners | Funding | United Kingdom |
| Exxel Pharma | 4 | Exxel Pharma is working to advance two in-licensed therapeutics that boost natural endocannabinoid signalling by FAAH inhibition. | Datinvest International | Acquisition | Canada |
| Flash Therapeutics | 3.9 | Flash Therapeutics is a new company developing proprietary RNA-based therapeutics and providing broad lentiviral development, manufacturing expertise and support. | Vectalys, FlashCell, AURIGA IV Bioseed | Merger Agreement | France |
| IntelGenx Technologies | 3.2 | IntelGenx Technologies Corp. announces the closing of the previously announced offering by way of private placement. In connection with the Offering, the Company issued 320 units at a subscription price of U.S.$10,000 per Unit for gross proceeds of U.S.$3,200,000. The Corporation intends to use the proceeds for its Montelukast phase 2a clinical trial and for general working capital purposes. | Cantone Research, Inc. | Private Placement | Canada |
| Polyneuron Pharmaceuticals | 3.2 | The proceeds will be used to advance its lead asset, PN-1007, to clinical development for the treatment of the rare nervous system disease, anti-MAG neuropathy, and advance additional applications of its Antibody-Catch™ technology platform. This technology enables the chemical design of injectable, biodegradable glycopolymers to eliminate autoimmune disease-causing autoantibodies, while leaving the immune system intact. | Zürcher Kantonalbank | Seed Financing | Switzerland |
| Arena Pharmaceuticals | 3 | Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders | Outpost Medicine | License Agreement | United States |
| Oasmia Pharmaceutical | 2.9 | Oasmia Pharmaceutical AB (publ) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with an interest rate of 8 per cent per year directed to and placed with a limited group of investors and paid in cash (the “Private Placement”). The convertible instrument issue is expected to provide the Company with SEK 26,000,000 before transaction related costs. | | Private Placement | Sweden |
| Indee Labs | 2.6 | Indee Labs received US$2.6M in venture financing extending its seed-stage funding to more than US$5.4M (AU$7.1M). This will accelerate the development of Indee Labs’ gene therapy manufacturing technology into a product that biotechnology companies can use for discovery-stage research. | Founders Fund’s Science, Main Sequence Ventures | Seed Financing | United States |
| Nanoco Group plc | 2.4 | The total value of milestones in this programme triggered to date is £2.6 million. The Partner is funding the capital expenditure required to expand the manufacturing capabilities of Nanoco's existing Runcorn facility in order to supply the Partner with commercial volumes of product. This process is already underway, with an agreement reached in March to take over 10,000 sq. ft. of additional space in Runcorn to build a state-of-the-art production facility in order to commence commercial supply | Undisclosed US-listed partner | Milestone Payment | United Kingdom |
| Canopy Biosciences | 2.4 | Canopy Biosciences is a fast-growing research tools company focusing on gene editing and expression analysis. The company seeks out advanced technologies for commercialization of high-tech products and services in the research tools space. Research tools have minimal development time and no regulatory risk. | BioGenerator, Kingdom Capital | Series A Financing | United States |
| Melinta Therapeutics | 2.3 | Melinta’s novel pyrrolocytosine compounds are a novel class of antibiotics from the company’s ESKAPE pathogen Program, a program based on Melinta’s proprietary drug discovery platform focused on developing breakthrough antibiotics for bacterial “superbugs” by targeting the bacterial ribosome. | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) | Partnership | United States |
| MannKind Corporation | 2.2 | Under the terms of the agreement, Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza® in India, including approval from the Drug Controller General of India. Cipla will also be responsible for all marketing and sales activities of Afrezza in India. MannKind is responsible for supplying Afrezza to Cipla. | Cipla | Marketing and Distribution Agreement | India |
| Scioto Biosciences | 2.2 | Scioto Biosciences offers a noteworthy solution with its microbiome platform to combat a serious condition impacting premature infants. Scioto Biosciences is a preclinical stage company developing innovative therapies devoted to having a transformative impact on the delivery of microbiome therapeutics. The Scioto Platform has the potential to enhance efficacy wherever probiotics are used such as diabetes, neurological disorders, gastrointestinal health, alternatives to in-feed antibiotics (in li | BioCrossroads | Series A Financing | United States |
| Bioasis Technologies, Inc. | 2.2 | The Company will use the net proceeds from the private placement to support ongoing research and development, clinical development, manufacturing and other activities in respect of the Company’s clinical development pipeline and for working capital and general corporate purposes. | Roth Capital Partners | Private Placement | Canada |
| CrystalGenomics, Inc. | 2 | CG-806 is being developed as a highly potent, oral small molecule for acute myeloid leukemia (AML), B-Cell malignancies and other hematologic malignancies. | Aptose Biosciences Inc. | Option Exercise Agreement | South Korea |
| OptiBiotix Health | 2 | OptiBiotix Health plc is developing advances that use the human microbiome to tackle obesity, high cholesterol and diabetes. The proceeds from the financing will be used to develop cholesterol and blood pressure reducing strain LPLDL®. | | Public Offering | United Kingdom |
| Frequency Therapeutics | 2 | Research Award will support translational preclinical and early-stage clinical research to address hearing dysfunction resulting from military service-related injuries | U.S. Department of Defense | Grants & Awards | United States |
| The Cambridge Partnership Ltd | 1.9 | RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom, announced today it has hired Nick Tait as group Chief Financial Officer and also completed the acquisition of the biotech-specialised accounting and back-office services company, The Cambridge Partnership Ltd. | RxCelerate | Acquisition | United Kingdom |
| Association of Community Cancer Centers (ACCC) | 1.5 | The RFP seeks individual grant requests up to a maximum of $150,000. In total, Pfizer will provide $1.5 million in funding for these quality improvement grants. | Pfizer | Grants & Awards | United States |
| Envisagenics, Inc. | 1.5 | This grant will provide $1.5 million over two years for Envisagenics’ continued development of SpliceCore, a cloud-based drug discovery platform that analyzes RNA sequencing (RNA-seq) data to accelerate RNA therapeutics discovery using innovative machine learning and artificial intelligence to identify new biomarkers and drug targets. | National Institutes of Health (NIH) | Grants & Awards | United States |
| GeneNews Ltd | 1.5 | In lieu of making a cash payment by the Company, certain arm's length providers will accept Units for an aggregate of Cdn$380,831, and a director, who is also a shareholder, will participate for Cdn$561,770 in lieu of repayment in cash. | | Private Placement | Canada |
| Emergex Vaccines Holding Limited | 1.3 | This grant will cover 70% of the cost of developing Emergex’s flu vaccine programme over a period of two years. It will be used to complete preclinical toxicology and validation studies and the manufacturing of the vaccine in accordance with current Good Manufacturing Practice (cGMP). This will result in clinical batches of the vaccine which are ready for Phase I clinical testing in the first half of 2020. | Innovate UK | Grants & Awards | United Kingdom |
| Aspect Biosystems | 1 | Aspect’s Lab-on-a-Printer™ 3D bioprinting platform technology enables the rapid creation of functional living tissues. The therapeutic applications are broad and profound and have attracted the attention of global pharmaceutical and biotechnology companies. | Genome BC | Funding | Canada |
| IONTAS Limited | 0.74 | This Grant Funding will be used to further develop IONTAS’ ion-channel targeting KnotBody antibody platform to block pain transmission via Nav1.7. IONTAS has developed a Nav1.7-targeted KnotBody to block pain transmission. | Innovate UK | Grants & Awards | United Kingdom |
| GeoVax Labs, Inc. | 1 | The grant, entitled “Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus”, supports advanced preclinical testing of GeoVax’s vaccine candidate (designated GEO-ZM02) in non-human primates in preparation for human clinical trials. GEO-ZM02 is a novel vaccine approach to protect against Zika virus (ZIKV), using GeoVax’s Modified Vaccinia Ankara (MVA) vector to express the ZIKV non-structural protein 1 (NS1). | National Institute of Allergy and Infectious Diseases (NIAID), of the National Institutes of Health (NIH) | Grants & Awards | United States |
| Recursion Pharmaceuticals | 0.55 | The grant, awarded by the Bill & Melinda Gates Foundation, represents a collaborative effort between Recursion and the Winzeler Lab at UC San Diego School of Medicine to accelerate the discovery of drugs to treat malaria, and sets the stage for Recursion to further broaden its drug discovery platform into infectious disease. | Bill & Melinda Gates Foundation | Grants & Awards | United States |
| CF Patients | 0.4 | The Vertex All in for CF Scholarship program was established in 2017 to help people living with cystic fibrosis (CF) and their immediate family members pursue two-year, four-year or graduate degrees. Part of Vertex’s 10-year, $500 million corporate giving commitment, this year the company doubled the number of recipients to 80 to help more people in the CF community. | Vertex Pharmaceuticals | Scholarship | United States |
| EpiVax, Inc. | 0.33 | The funding will enable EpiVax to further develop the new Personalized Immunogenicity Assessment (PIMA) tool, for the individualized risk assessment of enzyme replacement therapy for Pompe Disease patients. | National Institutes of Health (NIH) | Grants & Awards | United States |
| Daiichi Sankyo, Takeda Pharmaceuticals | Undisclosed | Thermo Fisher will retain global commercialization rights for the test and will lead all filings of supplemental premarket approvals (sPMA) in order to seek approval from the U.S. Food and Drug Administration (FDA). Expansion of Oncomine Dx Target Test aligns with the company's strategic plan to further develop its test as a companion diagnostic (CDx) for multiple therapies. | Thermo Fisher Scientific | Commercialization Agreement | Japan |
| Wyss Institute at Harvard University | Undisclosed | Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that they will collaborate to further advance the Wyss Institute’s efforts to recode the entire genome of cell lines derived from humans and other species, and to develop new tools and methods facilitating this goal. | Cellectis | Partnership | United States |
| Vascugen Inc. | Undisclosed | Vascugen licensed the blood vessel formation technologies from the IU Innovation and Commercialization Office | Indiana University (IU) School of Medicine | License Agreement | United States |
| BioAutomation Corporation | Undisclosed | LGC has today announced a further strengthening of its nucleic acid chemistry (NAC) offering with the acquisition of BioAutomation Corporation (BioAutomation), manufacturer of the renowned MerMade oligo synthesis instruments. | LGC Limited | Acquisition | United States |
| SFJ Pharmaceuticals Group | Undisclosed | Agreement enables Merck to further develop abituzumab through a novel risk-sharing collaboration agreement. SFJ Pharmaceuticals Group to develop abituzumab as a first-line treatment for metastatic colorectal cancer (mCRC) in combination with Erbitux® and chemotherapy. Clinical program will concentrate on patients with RAS wild-type left-sided tumors with high ???6 integrin expression. | Merck KGaA | Collaboration | United States |
| Telix Pharmaceuticals Limited | Undisclosed | Telix Pharmaceuticals Limited (Telix), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has selected Goodwin Biotechnology, Inc. (Goodwin) to optimize the process for cGMP manufacturing of its renal cancer imaging antibody drug conjugate TLX-250.The product will be used in Telix's Phase III clinical study for the diagnostic imaging and staging of patien | Goodwin Biotechnology, Inc. | Manufacturing Partnership | Australia |
| NeuroVive Pharmaceutical AB | Undisclosed | NeuroVive’s TBI drug NeuroSTAT is currently in phase II clinical development. NeuroSTAT has shown a good safety and pharmacokinetic profile in a recently completed phase II study in TBI patients conducted at Rigshospitalet in Copenhagen, Denmark. | TRACK-TBI | Partnership | Sweden |
| Kramer Laboratories | Undisclosed | Kramer is a recognized leader in OTC foot care products. The Company's portfolio includes leading foot care brands such as The Original Fungi-Nail® Toe & Foot® and HC Max™, as well as the Safetussin® brand of specialty cough solutions. The Company's products are sold in over 60,000 stores nationwide, including major drug, food and mass merchandiser outlets. | Avista Capital Partners, Dana Holdings | Acquisition | United States |
| Bactevo Ltd | Undisclosed | This collaboration leverages Bactevo’s revolutionary TIME (Totally Integrated Medicines Engine) platform designed specifically to combine medicinally-relevant ‘tagless’ chemical diversity with ultra-fast phenotypic or molecular target screening in human samples, to enhance speed, efficiency and quality of identifying novel in vivo enabled leads for undisclosed Boehringer Ingelheim programs of interest. | Boehringer Ingelheim | Collaboration | United Kingdom |
| ERS Genomics | Undisclosed | Licence provides EVOTEC's partners with unique integrated solution to identify novel disease-modifying genes; builds upon existing expertise on phenotypic screening, IPSC and disease biology. The new licence from ERS Genomics Limited complements and expands Evotec's existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others. | Evotec AG | License Agreement | Ireland |
| C4X Discovery | Undisclosed | The collaboration utilises both companies’ drug discovery technologies, in particular C4XD’s Taxonomy3® novel target identification platform and ETX’s Network-driven Drug Discovery (NDD) capabilities. Teams from both companies will use the outputs from C4XD’s Taxonomy3® genetic analysis of PD and apply an NDD approach to identify novel intervention strategies which it is expected will lead to new approaches for the treatment of PD. | e-Therapeutics plc | Collaboration | United Kingdom |
| Endoceutics, Inc. | Undisclosed | Intrarosa™ (Prasterone) has been developed for the treatment of women experiencing moderate to severe dyspareunia, which is an outcome of vulvovaginal atrophy that occurs due to menopause. Intrarosa™ is a unique non-estrogen product that is administered locally in order to exert an action limited to the vagina. | Mundipharma GmbH | License Agreement | Canada |
| Quartzy | Undisclosed | Through Quartzy, BioBuilt’s labs will be able to consolidate their purchasing workflows using the Quartzy Shop, the nation’s most comprehensive and diverse digital catalog of lab supplies containing more than two million products sourced from over 1,000 of the life science industry’s leading suppliers. The time-savings made possible by the Quartzy Shop will allow science teams to direct greater focus towards their research rather than wasting it managing multiple supplier relationships. | BioBuilt | Partnership | United States |
| aTen Therapeutics Limited | Undisclosed | "IONTAS will apply its technologies to overcome limitations of other platforms to generate therapeutic leads against pre-defined specification from aTen, to help its current pipeline progress." | IONTAS Limited | Collaboration | United Kingdom |
| Genohm | Undisclosed | Acquisition will enable Agilent to provide a single informatics solutionnacross laboratory and operational domains | Agilent Technologies, Inc. | Acquisition | Switzerland |
| Flatiron Health | Undisclosed | Bristol-Myers Squibb will use Flatiron’s real-world data to accelerate its research and development efforts, as well as improve its ability to generate additional evidence on the use of its cancer medicines outside of clinical trials. | Bristol-Myers Squibb | Collaboration Expansion | United States |
| Roivant Sciences | Undisclosed | monARC activates disease-specific patient research networks to enable greater participation in clinical trials and provide pre-screening analytics. monARC’s clinical trial platform employs remote monitoring and digital communication to broaden patient access, reduce site visits, and enable virtual clinical trials. Roivant to leverage monARC digital engagement platforms and patient networks to improve clinical research and expand access to underserved communities. | monARC Bionetworks, Inc. | Integration Agreement | Switzerland |
| MenoGeniX, Inc | Undisclosed | The National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant for the clinical development of MNGX-100, a version of a naturally-occurring human blood protein, for the treatment of menopausal hot flashes. | National Institute on Aging (NIA) of the National Institutes of Health (NIH) | Grants & Awards | Canada |
| Medpace | Undisclosed | With support from Medpace, Ritter Pharmaceuticals will conduct a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in the United States, in approximately 525 patients to evaluate the efficacy, safety, durability, and tolerability of RP-G28 in patients with lactose intolerance (LI). | Ritter Pharmaceuticals, Inc. | Clinical Collaboration | United States |
| Microsoft Corp. | Undisclosed | This week, Fred Hutchinson Cancer Research Center and its Seattle-area neighbor Microsoft Corp. announced a unique collaboration agreement to develop and pilot test technology to help cancer patients avoid the emergency room through better management of their chemotherapy side effects. | Fred Hutchinson Cancer Research Center | Collaboration | United States |
| Lonza Portsmouth Manufacturing Site | Undisclosed | The new facilities have been designed to ensure reliable delivery of innovative medicines. With a strong focus on automation, Lonza is implementing full-suite process analytic technology (PAT) and advanced multi-variate analysis (MVA) to ensure consistent performance. | Lonza Pharma & Biotech | Manufacturing Investment | United States |
| Leipzig University | Undisclosed | The exclusive option agreement allows the Company to license rights to "LymPro Test 2.0" which incorporates LymPro Test results with those of amyloid PET imaging for the diagnosis of Alzheimer's disease. | Amarantus Bioscience Holdings, Inc. | Option Agreement | Germany |
| Zettlex | Undisclosed | Celera Motion is a market leading provider of motion control components and subsystems for OEMs. The company offers precision encoders, motors, and customized mechatronic solutions that help customers solve challenging motion control problems. | Novanta Inc. | Acquisition | United Kingdom |
| Invitae Corporation | Undisclosed | Sarepta's President and CEO - "Sarepta's goal is to treat 100% of eligible individuals with DMD and using the best tools to enable earlier genetic-based identification of patients is a necessary element to eventually achieving that aspiration." | Sarepta Therapeutics, Inc. | Partnership | United States |
| Endo International plc | Undisclosed | Lannett Company, Inc. (NYSE: LCI) today announced that it has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International plc for an upfront payment plus future milestone payments. The portfolio primarily consists of oral solutions with a few semi-solid products. For the 12 months ended March 2018, combined sales of the acquired products were in excess of $175 million, according to IMS. | Lannett Company, Inc. | Asset Acquisition | United States |
| Pear Tree Pharmaceuticals, Inc. | Undisclosed | Agreement intends to broaden Company’s product portfolio within women’s reproductive health with novel clinical candidate, positioning Company with first in class candidates in contraception, sexual health and vaginal health | Daré Bioscience | Merger Agreement | United States |
| Provention Bio, Inc. | Undisclosed | Coxsackievirus B appears to be an important trigger for type 1 diabetes. PRV-101 will be developed using Intravacc’s proven and well-established platform technology, including certain proprietary cell lines and production processes. Provention, in partnership with Intravacc, Vactech and L2D is now developing its CVB vaccine for large scale manufacture of clinical trial material in accordance with current Good Manufacturing Practices (cGMP). | Intravacc | Development and Manufacturing Agreement | United States |
| Carna Biosciences, Inc | Undisclosed | Under the agreement, National Cancer Center and Carna Biosciences will collaborate on drug discovery research to develop a novel anticancer drug with new mechanisms of action that have been discovered by Dr. Kenkichi Masutomi, Chief, Division of Cancer Stem Cell at National Cancer Center Research Institute. | National Cancer Center Japan | Research Collaboration | Japan |
| Shuwen Biotech | Undisclosed | Abcam, a global leader in the supply of life science research tools, today signed a Memorandum of Understanding (MoU) with Shuwen Biotech, a leading player in the development and commercialization of companion diagnostics (CDx). Through the agreement, Abcam and Shuwen will jointly leverage their respective capabilities, in producing high-quality antibodies and CDx kit development and commercialization, to better serve the needs of the pharma industry. | Abcam | Memorandum of Understanding (MoU) | China |
| Evotec AG | Undisclosed | Carna will access Evotec's INDiGO platform to accelerate the development of its programme CB-1763, which is being developed for the treatment of blood cancer. Carna has another reversible BTK inhibitor in pre-clinical development, AS-871, a novel non-covalent BTK inhibitor targeting autoimmune diseases. AS-871 is also undergoing IND-enabling studies in collaboration with Evotec. | Carna Biosciences, Inc. | Collaboration | Germany |
| MediciNova, Inc. | Undisclosed | This randomized, double-blind, placebo-controlled, outpatient study plans to enroll 50 non-treatment seeking individuals with moderate-to-severe alcohol use disorder (AUD) | University of California, Los Angeles (UCLA) | Clinical Collaboration | United States |
| The Rockefeller University | Undisclosed | The collaboration calls for scientists at Rockefeller to use Hemogenyx's new type of humanized mice for autoimmune disease modelling in an effort to develop new treatments for autoimmune diseases - specifically Lupus. | Hemogenyx Pharmaceuticals PLC | Research Collaboration | United States |
| XtalPi Inc. | Undisclosed | Building upon XtalPi's existing relationship with Pfizer for crystal structure prediction (CSP), this research collaboration aims to help XtalPi and Pfizer further advance their capabilities in computation-based rational drug design and solid-form selection. | Pfizer Inc. | Collaboration | United States |
| GenomeDx Biosciences | Undisclosed | GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics | Janssen Pharmaceuticals | Collaboration | United States |
| Dolomite Bio | Undisclosed | Single cell data analysis enables researchers to gain useful insights into the diversity and state of single cells in a particular sample, which is fundamental for research into many diseases and immunity. However, analyzing single cell data can be challenging without prior advanced bioinformatics skills or in-house capabilities. | Partek Incorporated | Collaboration | United Kingdom |
| Lunatus | Undisclosed | Under the terms of the partnership, INSYS Therapeutics’ responsibilities will include supplying SUBSYS® to Lunatus, whose responsibilities will include obtaining the required regulatory approvals to commercialize SUBSYS® in the licensed territory. | INSYS Therapeutics, Inc. | License Agreement | Middle East |
| Autolus Limited | Undisclosed | Autolus Limited (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it has filed a registration statement on Form F-1 (“Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”) | | Registered Public Offering (Convertible Senior Notes) | United Kingdom |
| CEVEC Pharmaceuticals GmbH | Undisclosed | CAP(R)Go provides unique opportunity for CSL to develop highly differentiated recombinant C1 Esterase Inhibitor (C1-IHN) proteins for Hereditary Angioedema (HAE) and other potential indications | CSL Limited | License Agreement | Germany |
| Geisinger Health System | Undisclosed | Geisinger Health System announced at the HLTH conference in Las Vegas that it plans to expand its population health genomics program from research into clinical practice. It will do so by sequencing patient’s DNA as part of standard care. | Regeneron Genetics Center | Collaboration | United States |
| Cytox | Undisclosed | The Cytox genoBAR research test is intended to help pharma, biotech, and sponsors of large cohort studies reduce the time and high cost associated with identifying and stratifying subjects for clinical trials. The work performed by Cytox and AKESOgen resulted in over 99% concordance between the SNPs used in the PRS identified from blood and saliva samples collected from the same subjects and run on the Cytox variaTECT™ microarray on the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrumen | AKESOgen | Collaboration | United Kingdom |
| PHAST GmbH | Undisclosed | PHAST as a service provider for the research focused pharmaceutical industry has continuously grown over the past to meet the challenges of the market. The major increase of outsourcing activities are demanding a consistent expansion of the spectrum of analytical services as well as the laboratory capacity. To keep up with the market’s speed and the trend of consolidation, Eurofins’ support is highly welcomed. This includes both, speed in the field of IT integration and growth of additional lab | Eurofins BioPharma Services Holding GmbH | Acquisition | Germany |
| MacroGenics | Undisclosed | Provention acquires PRV-031 (teplizumab) and plans to initiate pivotal Phase 3 clinical trial to intercept early-onset type 1 diabetes, a pediatric orphan indication. Provention licenses and plans to advance PRV-3279 (formerly MGD010) as a potential treatment for systemic lupus erythematosus | Provention Bio | License Agreement | United States |
| PANTHERx | Undisclosed | JYNARQUE™ is a selective vasopressin V2-receptor antagonist. This means it blocks vasopressin, an anti-diuretic hormone secreted by the pituitary gland, which plays a key role in the fluid balance of the kidneys. By blocking this hormone, the drug can decrease cyst-cell proliferation and fluid secretion, which ultimately can reduce cyst growth. | Otsuka America Pharmaceutical, Inc. | Distribution Agreement | United States |
| Aegerion Pharmaceuticals, Inc. (Novelion Therapeutics Inc.) | Undisclosed | Amryt estimates there may be up to 450 additional patients who could benefit from treatment with Lojuxta across the countries covered by the extended agreement, representing an increase of approximately 25% in the total number of addressable patients in the Amryt territories. Amryt is actively seeking distribution partners in these new territories. | Amryt Pharma plc | License Agreement | Japan |
| Iovance Biotherapeutics | Undisclosed | Synergies between RXi's self-delivering RNAi (sd-rxRNA®) therapeutic platform and Iovance's TIL cell therapy approach will be explored preclinically. | RXi Pharmaceuticals Corporation | Material Transfer Agreement | United States |
| Catalent Pharma Solutions | Undisclosed | Under the agreement, Catalent Biologics will provide cell line development and support cGMP manufacturing activities from Phase 1 through to commercial stages at its state-of-the-art biologics manufacturing facility in Madison, Wisconsin. | Valerius Biopharma AG | Collaboration | United States |
| Toyama Chemical Co., Ltd., Taisho Pharmaceutical Holdings Co Ltd. | Undisclosed | FUJIFILM Holdings conducts its pharmaceutical business focused on the small molecule pharmaceutical products of TOYAMA CHEMICAL and the diagnostic and therapeutic radiopharmaceuticals of FUJIFILM RI Pharma. The merger company has been named as FUJIFILM Toyama Chemical Co., Ltd. | Fujifilm Holdings Corp | Merger Agreement | Japan |
| Harvard University | Undisclosed | The licensed technology platform, which includes access to base editing and associated technologies that enhance the targeting scope of base editing, opens a wide range of human genetic conditions to the therapeutic promise of genome editing. | Beam Therapeutics | License Agreement | United States |
| ScienceVision | Undisclosed | Under the partnership, ScienceVision will commercialize and distribute the PierianDx Clinical Genomics Workspace™ (CGW) platform for clinical genomic informatics, classification, interpretation, and clinical reporting. Hospitals, cancer centers, and genomic laboratories throughout Malaysia and Southeast Asia will now have access to PierianDx’s CGW platform for clinical genomic analysis and insight. | PierianDx | Distribution Agreement | Malaysia |
| Case Western Reserve University | Undisclosed | Together these have been shown to be highly accurate in detecting Barrett’s Esophagus, the primary precursor to the most common and lethal form of esophageal cancer caused by Gastroesophageal Reflux Disease (GERD), commonly known as heart burn or acid reflux. | PAVmed | License Agreement | United States |
| Supply Chain Wizard | Undisclosed | Partnering with Supply Chain Wizard equips QPSI with the latest and most effective IoT technology solutions, including a fully integrated Digital Factory suite of solutions (OEE Tracker, Scheduler and Digital Logbook for primary and secondary packaging operations). | Quality Packaging Specialists Int'l (QPSI) | Alliance | United States |
| Stelis Biopharma | Undisclosed | Stelis chose Merck for its best-in-class single-use manufacturing components for flexible operations and better regulatory compliance. Merck will bring its process know-how and application knowledge from global experts to help establish the single-use platform technologies at Stelis. | Merck | Partnership | India |
| Uppsala University | Undisclosed | The new extended research collaboration aims to develop innovative technologies to increase the passage of antibodies also into nerve cells. This can be of great value for the diagnosis and treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. | Bioarctic Neuroscience AB | Collaboration Extension | Sweden |
| TEDOR Pharma, Inc., | Undisclosed | DORA Ventures is a newly formed investment vehicle, owned and controlled by Laura Iorio, Chairwoman of TEDOR Pharma, and Doug Drysdale, President and CEO of TEDOR Pharma. Iorio has served as Chairwoman of TEDOR Pharma since 2009. Drysdale previously served as Chairman and CEO of Pernix Therapeutics (PTX) and as CEO of Alvogen, Inc. | DORA Ventures, Inc. | Funding | United States |
| DPS Group | Undisclosed | DPS Group, the engineering and construction management firm with operations and projects across Europe and the US has been awarded a major contract from the global pharmaceutical company AstraZeneca to provide Engineering, Procurement, Construction Management and Validation (EPCMV) services for small and medium sized projects on AstraZeneca’s pharmaceutical site in Södertälje, Sweden. | AstraZeneca PLC | Contract Agreement | Ireland |
| Edico Genome | Undisclosed | Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. | Illumina, Inc. | Acquisition | United States |
| International Association of Forensic Nurses | Undisclosed | Elsevier, the information analytics business specializing in science and health, and part of RELX Group, announced today that it will collaborate with the International Association of Forensic Nurses (IAFN) to enhance Elsevier's Clinical Skills for emergency nursing. | Elsevier | Collaboration | Worldwide |
| J. Kiffin Penry Epilepsy Education Programs | Undisclosed | SK life science has a pipeline of six products in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others. The company's lead product is cenobamate, an investigational compound that is being studied as a potential treatment option for patients with epilepsy. | SK Life Science, Inc. | Grants & Awards | United States |
| AGC Biologics | Undisclosed | AGC Biologics has provided comprehensive development and validation services for margetuximab since 2014, and plans to implement a transition to commercial supply services. Margetuximab is an investigational product that targets the human epidermal growth factor receptor 2, or HER2. HER2 is expressed by tumor cells in breast, gastroesophageal, bladder and other forms of solid tumor cancers, making it a key marker for biologic therapy. | MacroGenics, Inc. | Commercial Supply Agreement | United States |
| Memorial Sloan Kettering Cancer Center (MSK) | Undisclosed | The use of clonal master iPSC lines can overcome the complexity, heterogeneity and substantial costs associated with using cells from a patient or an allogeneic donor. Instead, iPSC-derived T-cell immunotherapies can be consistently and repeatedly mass produced and delivered in an off-the-shelf manner, significantly reducing the cost of, and time to, patient treatment. | Fate Therapeutics, Inc. | Expansion of License Agreement | United States |
| Emulate, Inc. | Undisclosed | AstraZeneca has announced a collaboration with Emulate to develop and embed the start-up’s Organs-on-Chips technology within its Innovative Medicines and Early Development (IMED) Drug Safety organisation laboratories. | AstraZeneca PLC | Partnership | United States |
| Ohr Pharmaceutical | Undisclosed | Vitrisa is acquiring the clinical database in order to use the clinical data set to run virtual clinical trials and evaluate innovative clinical strategies in wAMD. | Vitrisa Therapeutics, Inc. | Option Agreement | United States |
| Washington University | Undisclosed | The two-year collaboration will use Merck's genome-editing technology in research studies conducted by Dr. Jeffrey Gordon of the Washington University School of Medicine. The objectives of the research are to determine the differences between intestinal bacterial communities in healthy and malnourished children and to identify which characteristics of intestinal bacteria in healthy children are fundamental for healthy growth. | Merck KGaA | Collaboration | United States |
| ProMed BioSciences, Ltd. (Profectus BioSciences, Inc.) | Undisclosed | The joint venture will leverage Profectus' vaccine R&D expertise, clinically validated vaccine platform technologies, and pipeline of vaccine products in development with Medisun's expertise, established clinical network, and knowledge of local clinical, regulatory, and market access capabilities and is expected to be operational in the latter half of 2018. | Medisun Holdings Limited | Joint Venture | Hong Kong |
| GeneNews Ltd | Undisclosed | GeneNews, through Innovative Diagnostic Laboratory ("IDL"), its wholly-owned subsidiary in Richmond, Virginia, operates a full service reference lab focused on early cancer risk stratification and diagnosis and has a strong U.S. presence on the East and West coasts. AIM Laboratories operates a full service reference lab focused on routine blood testing and specializing in therapeutic drug monitoring for prescribed and illicit drugs and services about 20 States with particular strength in the M | AIM Laboratories | Partnership | Canada |
| Akums Drugs and Pharmaceuticals | Undisclosed | Akums will manufacture and supply products containing OptiBiotix's LPLDL® throughout India to maximise the financial return for both parties. Products containing LPLDL® have a unique ability to increase 'HDL' and reduce both bad cholesterol (LDL) and blood pressure, providing a clinically proven natural product to help reduce cardiovascular risk factors in countries with a high prevalence of these conditions. | OptiBiotix Health | Manufacturing and Supply Agreement | India |
| BrainScope | Undisclosed | The BrainScope One system to be used in Prevacus' upcoming Phase 1b drug study provides a multi-dimensional assessment of brain function including EEG measures, cognitive performance tests, and standard, digitized concussion assessment tests to aid in standardizing data collection across clinical sites. | Prevacus Inc. | Partnership | United States |
| PharmOut | Undisclosed | This new partnership offers a cost-effective and innovative validation solution to Australian companies. Combining the expertise of PharmOut's large team of validation consultants with the ValGenesis Validation Lifecycle Management System will deliver faster, cheaper validation services in Australia. | ValGenesis Inc | Partnership | Australia |
| Bioasis Technologies, Inc. | Undisclosed | Through this partnership Bioasis will have access to WuXi Biologics’ extensive expertise and technologies from cell line construction and development, cell culture process development, purification process development and formulation development. WuXi Biologics will focus on ensuring that Bioasis’ drug product candidates are manufactured with optimal formulation, stability and exceptional quality for the clinic. | WuXi Biologics | Collaboration | Canada |
| Oasmia Pharmaceutical AB | Undisclosed | With this move completed, AdvaVet, Inc. can begin to unlock value for Oasmia shareholders through the development and commercialization of two new chemotherapy drugs that specifically target companion animals. | AdvaVet, Inc. | Asset Transfer | Sweden |
| Verge Genomics | Undisclosed | This public-private consortium will combine VIB's cutting-edge single-nucleus RNA sequencing technology, UC San Diego's outstanding collection of tissue generously provided by patients and their families, and Verge's machine learning platform to generate and analyze new types of patient data at a resolution only recently made possible. | University of California San Diego, VIB | Partnership | United States |
| Aptinyx Inc. | Undisclosed | Allergan was granted option rights to a limited number of small molecules from the Aptinyx discovery platform under a research collaboration initiated in conjunction with its 2015 acquisition of Naurex, the predecessor company from which Aptinyx and its platform were spun out. | Allergan | Option Agreement | United States |
| Qualia Pharma | Undisclosed | Enzymatica has entered into a distribution agreement with Qualia Pharma for marketing and sales of ColdZyme® Mouth Spray on the Greek and Cypriot market. The background to the agreement is that Qualia Pharma acquired Life NLB on March 1, 2018. The distribution agreement that Enzymatica previously had with Life NLB is now being transferred to Qualia Pharma. | Enzymatica AB | Distribution Agreement | Greece |
| Eurofins Scientific | Undisclosed | Eurofins Scientific announces that it has signed an outsourcing agreement with Astellas to outsource one of its internal testing laboratories Astellas Analytical Science Laboratories, Inc. | Astellas Pharma Inc. | Outsourcing Agreement | Luxembourg |
| Kura Oncology | Undisclosed | OncoDNA will support patient enrolment for Kura’s ongoing HRAS tipifarnib trial in patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC). Tipifarnib is an inhibitor of farnesylation, a key cell signalling process implicated in cancer initiation and resistance to standard therapies. | OncoDNA | Clinical Collaboration | United States |
| Mayo Clinic | Undisclosed | Cytox will assess genetic risk for developing Alzheimer’s disease using its current commercially available approaches developed to run on the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform, in addition to new approaches under development. Mayo Clinic’s Alzheimer’s Disease Research Center will provide biobank samples from research participants classified as clinically normal, diagnosed with mild cognitive impairment and diagnosed with mild Alzheimer | Cytox | Collaboration | United States |
| Antibody Solutions | Undisclosed | The licensing agreement is for the use of The Trianni Mouse™, a best-in-class fully humanized transgenic mouse platform, to support its therapeutic antibody discovery programs. | Trianni, Inc. | License Agreement | United States |
| mAbxience (Insud Pharma Group) | Undisclosed | The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment | Amneal Pharmaceuticals, Inc. | License Agreement | Spain |
| ID Pharma | Undisclosed | The new licence is an important addition to Evotec’s iPSC platform, one of the most comprehensive in the industry. It further enhances Evotec’s broad iPSC capabilities in early drug discovery for treatments of a variety of conditions including nervous system diseases and diabetes. | Evotec AG | License Agreement | Japan |
| AcelRx Pharmaceuticals, Inc. | Undisclosed | Leerink Revelation Partners and Industry Ventures, along with other investors, have acquired AcelRx Pharmaceuticals (AcelRx) from Three Arch Partners III, Three Arch Associates III, Three Arch Partners IV, and Three Arch Associates IV. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company currently engaged in the development of two product candidates including DSUVIA™ (sufentanil sublingual tablet, 30 mcg) and Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) for r | Leerink Revelation Partners | Private Placement | United States |
| Quartzy | Undisclosed | This partnership follows the recent launch of Quartzy’s Redwood City fulfillment center. Located in close proximity to IndieBio’s labs, the new warehouse delivers a logistical advantage to the emergent biotech startups that often have limited lead time to spare on their orders and an unceasing need for consumables and reagents. | IndieBio | Partnership | United States |
| National Cancer Institute (NCI), Federal Communications Commission (FCC) | Undisclosed | The L.A.U.N.C.H. (Linking & Amplifying User-Centered Networks through Connected Health) program will use human-centered design methodologies to identify the needs of patients, caregivers and healthcare providers. | Amgen | Collaboration | United States |
| Curevo | Undisclosed | Curevo represents an important next step in GC Pharma's vaccine business. The new company will bring together GC Pharma's commercial scale vaccine development expertise and deep understanding of protein science with IDRI and MIBR's world class scientific expertise in vaccine, adjuvant and formulation development. Initial work will centre on advancing an innovative vaccine candidate against shingles to clinical stage. | Infectious Disease Research Institute, GC Pharma | Launch & Partnerships | United States |
| Eiger Biopharmaceuticals Inc. | Undisclosed | Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has expanded its licensing agreement with Merck, known as MSD outside the United States and Canada, to include rights to develop the investigational farnesyltransferase inhibitor lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria), a rare and fatal genetic condition characterized by accelerated aging in children. Th | Merck & Co., Eiger Biopharmaceuticals Inc. | License Agreement | United States |
| Pharmacyclics | Undisclosed | Oncternal’s CIRLL study (Cirmtuzumab and Ibrutinib targeting ROR1 for Lymphoma and Leukemia) is now underway, enrolling approximately 117 patients with MCL and CLL/SLL who have not received previous BTK inhibitor therapy. CIRLL is a randomized, open label, dose-finding study designed to evaluate the safety and efficacy of cirmtuzumab when given in combination with ibrutinib. The objective is to demonstrate that even more patients treated with the combination of cirmtuzumab plus ibrutinib will ac | Oncternal Therapeutics, Inc., | Clinical Collaboration | United States |
| Merus N.V. | Undisclosed | ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced that the company achieved an undisclosed milestone payment from Merus N.V. based on Merus’ use of MCLA-158, a bispecific antibody utilizing the GlymaxX® antibody-dependent cell-mediated cytotoxicity (ADCC)-enhancing technology in Merus’ Phase I clinical trial. | ProBioGen AG | Milestone Payment | The Netherlands |
| Euroclone Diagnostica S.r.l | Undisclosed | ICE COLD-PCR technology preferentially enriches mutant DNA sequences over wild-type (normal) DNA through selective amplification of the mutant DNA. | Precipio, Inc. | Distribution Agreement | Italy |
| Hadasit Medical Research Services and Development | Undisclosed | Recipharm, the contract development and manufacturing organisation (CDMO), has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological and chemical services. | Recipharm | Partnership | Israel |
| Angsana Molecular & Diagnostics Laboratory | Undisclosed | Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai, announce a partnership to market the MammaPrint® Breast Cancer Risk of Recurrence test and the BluePrint® Molecular Subtyping test to physicians across Southeast Asia, including Singapore, Malaysia, Vietnam, Brunei and Myanmar. | Agendia | Marketing and Distribution Agreement | Singapore |
| ePatientFinder | Undisclosed | This acquisition will enhance Elligo’s trial matching process by incorporating ePatientFinder’s technology platform. Using this platform, Elligo will streamline patient identification and feasibility through automation using electronic health record (EHR) data within Elligo’s network of providers. | Elligo Health Research | Asset Acquisition | United States |
| Bicycle Therapeutics | Undisclosed | THR-149 is a novel plasma kallikrein inhibitor identified and optimized by the Bicycle technology platform. The open-label, multicenter, dose escalation study will evaluate the safety of intravitreally administered THR-149 for the treatment of diabetic macular edema (DME). Initial study results are anticipated in mid-2019. | ThromboGenics NV | Milestone Payment | United Kingdom |
| Sandoz Canada (Novartis) | Undisclosed | The proposed acquisition of Novartis Technical Operations' sterile manufacturing facility and the adjacent Sandoz Development Center located on the Sandoz Canada campus in Boucherville, Quebec, is expected to be finalized in the next few months, following the completion of a number of closing conditions including receipt of anti-trust approvals. | Avara Pharmaceutical Service | Manufacturing Facility Acquisition | Canada |
| Beactica AB | Undisclosed | The collaboration agreement under which Beactica and Sanofi will work is based on previous work by Beactica scientists who have supported Sanofi with analysis of the interaction kinetics between insulin analogues and their two binding sites on the full-length insulin receptor. The present agreement extends towards research on the characterization of interactions between novel therapeutics under development at Sanofi and their target proteins. | Sanofi | Collaboration | Sweden |
| Centogene | Undisclosed | Under the terms of the agreement, CENTOGENE will collaborate with Aldeyra to globally identify patients with SLS and to understand the clinical spectrum of this disease. The goal of the agreeement is to support physicians and patients with early diagnosis through genetic testing that could potentially lead to the identification of novel therapeutic developments and raise awareness of the disease. | Aldeyra Therapeutics Inc. | Collaboration | Germany |
| Adaptive Biotechnologies | Undisclosed | Through this collaboration, the parties will work together to evaluate the clinical value of monitoring MRD negativity in isatuximab-treated MM patients. Adaptive will be responsible for seeking regulatory approvals for and commercialization of the clonoSEQ Assay in MM for select geographies. Adaptive will receive upfront payments and potential future milestone payments. Financial terms of the agreement were not disclosed | Sanofi | Collaboration | United States |
| Halma | Undisclosed | The partnership combines the strength of OurCrowd’s global network, robust deal flow pipeline and growing portfolio of 150 promising startups along with the reach and business objectives of Halma to seek innovative products and services in digital health, infrastructure and environmental analytics and insights. | OurCrowd | Partnership | Israel |
| Pharmanest AB | Undisclosed | SHACT is a novel technology that provides pain relief on vaginal mucosal tissue. In a clinical study conducted in Sweden, the SHACT treatment was associated with significant reduction of pain and discomfort in women undergoing gynecological interventions without causing bothersome side effects. | Acerus Pharmaceuticals Corporation | Commercialization Agreement | Canada |
| Ipsen | Undisclosed | MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization. | Institute for Applied Cancer Science (MD Anderson) | Partnership | France |
| Adaptive Biotechnologies | Undisclosed | Through this collaboration, the parties will work together to evaluate the clinical value of monitoring MRD negativity in isatuximab-treated MM patients. Adaptive will be responsible for seeking regulatory approvals for and commercialization of the clonoSEQ Assay in MM for select geographies. Adaptive will receive upfront payments and potential future milestone payments. Financial terms of the agreement were not disclosed | Sanofi | Collaboration | United States |
| Keio University Hospital, Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma | Undisclosed | With the aim of curing intractable immune-mediated inflammatory diseases, reverse translational research* for drug discovery research is being conducted worldwide using data on clinical samples analyzed with the latest technologies. Daiichi Sankyo defines the intractable and rare diseases that are difficult to be cured with current standards of care (SOC) as “New Horizon Areas,” and it aims to offer a new treatment option for patients by continuously creating advanced pharmaceuticals that will t | Daiichi Sankyo Company, Limited | Industry-Academia Consortium | Japan |
| Centre for Drug Research and Development | Undisclosed | Schrödinger will support hit triage, prioritization through prediction of physico-chemical liabilities, and antibody humanization. CDRD will provide a portfolio of targeted antibodies for undisclosed oncology indications. CDRC will provide a portfolio of targeted antibodies and Schrödinger will apply its advanced computation platform in order to prioritize these drug candidates and otherwise accelerate discovery. | Schrödinger, Inc. | Collaboration | Canada |
| Harbour Antibodies (Harbour BioMed) | Undisclosed | Co-offering combines AbCellera’s microfluidic single-cell screening platform with Harbour’s H2L2 transgenic mouse technology to create an end-to-end solution for the discovery of fully-human lead therapeutic antibodies. | AbCellera | Technology Agreement | United States |
| Nektar Therapeutics | Undisclosed | Syndax and Nektar have entered into a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar's NKTR-214, a CD122-biased agonist, in combination with entinostat, Syndax's oral, small molecule Class 1 specific HDAC inhibitor, in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 (programmed death receptor-1) agent. | Syndax Pharmaceuticals, Inc. | Clinical Collaboration | United States |
| BDD Pharma | Undisclosed | BDD's proprietary OralogiK™ technology enables the oral delivery of single, multi-dose or combination drugs at pre-determined times between one and 12 hours after administration to the patient. | Novartis Pharma AG | License Agreement | Scotland |
| Zai Lab Limited | Undisclosed | Crescendo Biologics has granted to Zai Lab a worldwide exclusive license to develop and commercialize its drug candidate for all indications. Zai Lab will be responsible fornconducting all regulatory filings, clinical studies, and commercialization activities. Crescendo's proprietary Humabody® therapeutics target a range of Autoimmune and Infectious Disease Indications. | Crescendo Biologics | License Agreement | China |
| Evotec AG, Fred Hutchinson Cancer Research Center | Undisclosed | LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development. Arix, Evotec and Fred Hutch plan to jointly select promising LAB591 research projects from the Fred Hutch labs. After developing a research validation plan, Evotec will conduct research in collaboration with the Fred Hutch faculty which will be seed funded by Arix. Once completed, and subject to the results, Arix and Evotec h | Arix Bioscience plc | Collaboration | United States |
| Premier Inc. | Undisclosed | Merck and Premier® will develop and test the combination of a software-based platform and a coordinator to provide surveillance, consultation, support and education to patients with C. diff at participating Premier member health systems. | Merck | Collaboration | United States |
| MD Anderson | Undisclosed | The collaborations will focus on Amgen's bispecific T cell engager (BiTE®), chimeric antigen receptor (CAR) T cell and small molecule programs. Amgen is advancing both types of T cell therapies against different targets and, in some cases, the same target. | Amgen | Collaboration | United States |
| FORMA Therapeutics | Undisclosed | FORMA Therapeutics and HitGen Initiate Multiyear Research Collaboration with which FORMA expands external discovery research footprint with dedicated unit at HitGen. | HitGen Ltd | Collaboration | United States |
| Takeda Pharmaceutical Company Limited | Undisclosed | Relugolix (TAK-385) is being developed as a gonadotropin-releasing receptor antagonist to be taken orally once daily against uterine fibroids, endometriosis and prostate cancer. | ASKA Pharmaceutical Co., Ltd. | License Agreement | Japan |
| Bayer Oncology | Undisclosed | Bayer is collaborating with the U.S. Department of Energy's Oak Ridge National Laboratory, based in Oak Ridge, TN, to produce actinium-227 (227Ac), the key radioisotope used in the production of the company's prostate cancer treatment Xofigo® (radium Ra 223 dichloride). | U.S. Department of Energy's Oak Ridge National Laboratory | Partnership | United States |
| Novartis | Undisclosed | The five products acquired by NTC from Novartis include Colircusi Gentadexa (aminoglycoside), Colircusi gentamicin and Oftalmolosa Cusi gentamicina (aminoglycoside), Oftalmolosa cusi erythromycin (macrolide), Oftalmolosa cusi aureomycin (tetracycline), and Oftacilox (fluoroquinolone) and are the most recent additions to the NTC portfolio | NTC Pharma | Asset Acquisition | Switzerland |
